Cargando…

PB2272: PI3KΔ INHIBITOR LINPERLISIB FOR PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF A PHASE 2 TRIAL

Detalles Bibliográficos
Autores principales:	Qiu, Lihua, Wang, Tingyu, Sun, Xiuhua, Su, Hang, Cao, Junning, LI, Zhi-Ming, Song, Yuqin, Zhang, LI, LI, Dengju, Wu, Huijing, Zhang, Wei, LI, Junmin, Zhou, Keshu, Zhou, Hui, Yang, Yu, LI, Zhifeng, Cen, Hong, Cai, Zhen, Zhang, Zhihui, Fu, Weijun, Jin, Jie, LI, Fei, Wu, Weixin, Gu, Xuekui, Zhu, Weiliang, Liu, Lihong, LI, Zengjun, Yi, Shuhua, Qiu, Lugui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428695/ http://dx.doi.org/10.1097/01.HS9.0000975820.37624.bc

Ejemplares similares

PB2269: PI3KΔ INHIBITOR LINPERLISIB FOR ELDERLY PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF A PHASE 2 TRIAL
por: Sun, Xiuhua, et al.
Publicado: (2023)

The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
por: Wang, Tingyu, et al.
Publicado: (2023)

P1119: THE ORAL PI3KΔ INHIBITOR LINPERLISIB FOR THE TREATMENT OF RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: A SINGLE-ARM MULTICENTER PHASE 2 CLINICAL TRIAL
por: wang, T., et al.
Publicado: (2022)

Serum LDH level may predict outcome of chronic lymphocytic leukemia patients with a 17p deletion: a retrospective analysis of prognostic factors in China
por: Li, Heng, et al.
Publicado: (2017)

MicroRNA-15a/16-1 cluster located at chromosome 13q14 is down-regulated but displays different expression pattern and prognostic significance in multiple myeloma
por: Li, Fei, et al.
Publicado: (2015)

Model-based clustering for identifying disease-associated SNPs in case-control genome-wide association studies
por: Xu, Yan, et al.
Publicado: (2019)

P1174: PI3K INHIBITOR LINPERLISIB COMBINED WITH GEMCITABINE AND OXALIPATIN (GEMOX) IN RELAPSED AND/OR REFRACTORY DLBCL: ANALYSIS BASED ON TUMOR BIOLOGY
por: Zhi-Ming, LI, et al.
Publicado: (2023)

A two‐part, single‐arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B‐cell malignancies
por: Song, Yuqin, et al.
Publicado: (2022)

Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies
por: Jiang, Bo, et al.
Publicado: (2021)

Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China
por: Li, Zengjun, et al.
Publicado: (2015)

Mechanisms of relaxant activity of BAY 41-2272 in rat tracheal smooth muscle in vitro
por: Toque, Haroldo AF, et al.
Publicado: (2009)

BCL-2 and MYC gain/amplification is correlated with central nervous system involvement in diffuse large B cell lymphoma at leukemic phase
por: Zou, Dehui, et al.
Publicado: (2017)

Differences in clinical characteristics and outcomes between patients with grade 3a and grades 1–2 follicular lymphoma: a real-world multicenter study
por: Zha, Jie, et al.
Publicado: (2023)

Family physicians’ questions about the COVID-19 pandemic: a content analysis of 2,272 helpline calls
por: McDougall, Allan, et al.
Publicado: (2023)

Prominent immune signatures of T cells are specifically associated with indolent B‐cell lymphoproliferative disorders and predict prognosis
por: Yi, Shuhua, et al.
Publicado: (2020)

Phosphodiesterases Regulate BAY 41-2272-Induced VASP Phosphorylation in Vascular Smooth Muscle Cells
por: Adderley, Shaquria P., et al.
Publicado: (2012)

The soluble guanylyl cyclase stimulator BAY 41-2272 increases differentiation and function of brown adipocytes
por: Etzrodt, Jennifer, et al.
Publicado: (2013)

BAY 41-2272 activates host defence against local and disseminated Candida albicans infections
por: Soeiro-Pereira, Paulo Vítor, et al.
Publicado: (2015)

Distinct clinical characteristics draw a new prognostic model for splenic marginal zone lymphoma in HBV high prevalent region
por: Yi, Shuhua, et al.
Publicado: (2017)

A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia
por: An, Gang, et al.
Publicado: (2021)

NO-independent regulatory site of direct sGC stimulators like YC-1 and BAY 41-2272
por: Becker, Eva Maria, et al.
Publicado: (2001)

PReS-FINAL-2272: Association of benign joint hypermobility syndrome with mitral valve prolapsed in Iranian children
por: Shiari, R, et al.
Publicado: (2013)

Serum high expression of miR-214 and miR-135b as novel predictor for myeloma bone disease development and prognosis
por: Hao, Mu, et al.
Publicado: (2016)

Detection of recurrent cytogenetic aberrations in multiple myeloma: A comparison between MLPA and iFISH
por: Zang, Meirong, et al.
Publicado: (2015)

Relaxant effect of BAY 41-2272 and BAY 58-2667 in the gastrointestinal tract of apo-sGC mice
por: Cosyns, Sarah, et al.
Publicado: (2011)

PB2272: THERAPY AND HOSPITAL MORTALITY PREDICTORS IN HEMATOLOGICAL PATIENTS WITH 4 GRADE NEUTROPENIA AND CONCOMITANT CORONAVIRUS INFECTION
por: Kaluzskaya, K., et al.
Publicado: (2022)

High incidence of MYC and BCL2 abnormalities in mantle cell lymphoma, although only MYC abnormality predicts poor survival
por: Yi, Shuhua, et al.
Publicado: (2015)

Clinical features and outcomes of 1845 patients with follicular lymphoma: a real-world multicenter experience in China
por: Zha, Jie, et al.
Publicado: (2021)

Addition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic Leukemia
por: Zhang, Ye, et al.
Publicado: (2016)

Del17p does not always significantly influence the survival of B-cell chronic lymphoproliferative disorders
por: Yi, Shuhua, et al.
Publicado: (2017)

Cytogenetic aberrations of lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia in Chinese patients
por: Xiong, Wenjie, et al.
Publicado: (2023)

Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China
por: Yan, Yuting, et al.
Publicado: (2023)

Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma
por: Li, Fei, et al.
Publicado: (2015)

Antihypertrophic actions of NO-independent soluble guanylyl cyclase (sGC) ligands BAY 41-2272 and BAY 58-2667 in vitro
por: Ritchie, Rebecca, et al.
Publicado: (2009)

2272. Evaluation of Clinical Features, Carbapenem Resistance and Risk Factors of Klebsiella Species: A 4-Year Retrospective Study in Turkey
por: Umit, Zuhal, et al.
Publicado: (2019)

Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma: a phase 1, dose-escalation study (MMY1003)
por: Jing, Hongmei, et al.
Publicado: (2022)

BAY 41-2272 Attenuates CTGF Expression via sGC/cGMP-Independent Pathway in TGFβ1-Activated Hepatic Stellate Cells
por: Chen, Po-Jen, et al.
Publicado: (2020)

c-MYC and reactive oxygen species play roles in tetrandrine-induced leukemia differentiation
por: Wu, Guixian, et al.
Publicado: (2018)

Analysis and Research on Starch Content and Its Processing, Structure and Quality of 12 Adzuki Bean Varieties
por: Zhang, Lei, et al.
Publicado: (2022)

Predictors of Hospital Readmission within 30 Days after Coronary Artery Bypass Grafting: Data Analysis of 2,272 Brazilian Patients
por: Chiorino, Camilla do Rosário Nicolino, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_d6l90o8qc27j988i79umj2f5ne